摘要:
Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
摘要:
L'invention concerne un procédé de préparation de la cis-N-méthyl-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydro-1-naphtylamine ou sertraline racémique répondant à la formule (I), sous forme de sel, à partir de la 4-(3,4-dichlorophényl)-tétralone de formule (II), selon lequel (a) on fait réagir la 4-(3,4-dichlorophényl)-tétralone de formule (II) avec le N-méthylformamide en présence d'acide formique, (b) on traite le milieu réactionnel obtenu selon (a) par une base, et (c) on sépare le sel de sertraline racémique, par cristallisation sélective avec un acide. L'invention concerne aussi la N-méthyl-formamide-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydro-1-naphtylamine et son utilisation pour obtenir la sertraline racémique.
摘要:
L'invention concerne un procédé de préparation de la cis-N-méthyl-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydro-1-naphtylamine ou sertraline racémique répondant à la formule (I), sous forme de sel, à partir de la 4-(3,4-dichlorophényl)-tétralone de formule (II), selon lequel (a) on fait réagir la 4-(3,4-dichlorophényl)-tétralone de formule (II) avec le N-méthylformamide en présence d'acide formique, (b) on traite le milieu réactionnel obtenu selon (a) par une base, et (c) on sépare le sel de sertraline racémique, par cristallisation sélective avec un acide. L'invention concerne aussi la N-méthyl-formamide-4-(3,4-dichlorophényl)-1,2,3,4-tétrahydro-1-naphtylamine et son utilisation pour obtenir la sertraline racémique.
摘要:
The invention provides the substantially geometrically pure cis-stereoisomeric form of a compound of formula (I) and the substantially geometrically and optically pure cis-stereoisomeric form of a compound of formula (II) wherein R1 is H or C¿1?-C4 alkyl, together with processes for their preparation. The compounds are intermediates for the preparation of the antidepressant agent known as sertraline.
wherein Ar¹ and Ar² are phenyl, R²-substituted phenyl, heteroaryl or R²-substituted heteroaryl, wherein R² is 1 to 3 substituents independently selected from the group consisting of halogeno, hydroxy, lower alkyl, lower alkoxy, nitro, amino, lower alkylamino and lower dialkylamino; X, Y and Z are -CH₂-, -CH(alkyl)-, -C(alkyl)₂-, -NH-, -N(alkyl)-, -O- or SO r , wherein r is 0, 1 or 2, and m, n and p are 0 or 1; R¹ is an alkyl chain of 1 to 25 carbon atoms; an alkyl chain substituted by one or more optionally substituted phenyl or heteroaryl groups; an alkyl chain -O-, -SO r , phenylene, R²-substituted phenylene, heteroarylene or R²-substituted heteroarylene groups; an interrupted alkyl chain substituted by one or more optionally substituted phenyl or heteroaryl groups; an alkyl chain of 4 to 25 carbon atoms, interrupted by one or more -NH-, -C(O)- or -N(lower alkyl)- groups; an interrupted alkyl chain of 4 to 25 carbon atoms substituted by one or more phenyl, R²-substituted phenyl, heteroaryl or R²-substituted heteroaryl groups; a diphenylamino group; a di-(R²-substituted phenyl)amino group; a diheteroarylamino group; or a di-(R²-substituted heteroaryl)amino group; or a pharmaceutically acceptable salt thereof, useful in the treatment of artherosclerosis are disclosed.
摘要:
The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention also relates to methods for the production of said inventive compounds, in addition to methods for linking the thus obtained monomer 3-amino adamantane-1-carboxylic acid derivatives in order to form oligomers. The inventive compounds are suitable for use as anti-viral active substances, artificial ion channels and for the therapy, diagnosis and prophylaxis of diseases, wherein a defect of the GA-BA-system occurs.
摘要:
Treatment of central nervous system disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine and with (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine is also disclosed.